|
Gene: SECISBP2 |
Gene summary for SECISBP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SECISBP2 | Gene ID | 79048 |
Gene name | SECIS binding protein 2 | |
Gene Alias | SBP2 | |
Cytomap | 9q22.2 | |
Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | B4DZC7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79048 | SECISBP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.59e-02 | 2.86e-01 | -0.1954 |
79048 | SECISBP2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.12e-10 | 8.22e-01 | 0.281 |
79048 | SECISBP2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.38e-03 | -2.26e-01 | 0.3005 |
79048 | SECISBP2 | A015-C-203 | Human | Colorectum | FAP | 3.07e-25 | -1.87e-01 | -0.1294 |
79048 | SECISBP2 | A015-C-204 | Human | Colorectum | FAP | 1.28e-02 | 1.05e-02 | -0.0228 |
79048 | SECISBP2 | A014-C-040 | Human | Colorectum | FAP | 5.00e-03 | -9.28e-02 | -0.1184 |
79048 | SECISBP2 | A002-C-201 | Human | Colorectum | FAP | 8.96e-10 | -1.27e-01 | 0.0324 |
79048 | SECISBP2 | A002-C-203 | Human | Colorectum | FAP | 2.33e-02 | -1.42e-02 | 0.2786 |
79048 | SECISBP2 | A001-C-108 | Human | Colorectum | FAP | 7.03e-12 | -1.33e-02 | -0.0272 |
79048 | SECISBP2 | A002-C-205 | Human | Colorectum | FAP | 1.01e-15 | -1.80e-01 | -0.1236 |
79048 | SECISBP2 | A015-C-006 | Human | Colorectum | FAP | 4.17e-11 | -1.47e-01 | -0.0994 |
79048 | SECISBP2 | A015-C-106 | Human | Colorectum | FAP | 4.01e-07 | 1.66e-02 | -0.0511 |
79048 | SECISBP2 | A002-C-114 | Human | Colorectum | FAP | 1.41e-13 | -1.58e-01 | -0.1561 |
79048 | SECISBP2 | A015-C-104 | Human | Colorectum | FAP | 7.27e-27 | -4.41e-02 | -0.1899 |
79048 | SECISBP2 | A001-C-014 | Human | Colorectum | FAP | 2.48e-12 | 1.32e-02 | 0.0135 |
79048 | SECISBP2 | A002-C-016 | Human | Colorectum | FAP | 4.29e-17 | -1.05e-01 | 0.0521 |
79048 | SECISBP2 | A015-C-002 | Human | Colorectum | FAP | 5.09e-09 | 7.23e-03 | -0.0763 |
79048 | SECISBP2 | A001-C-203 | Human | Colorectum | FAP | 3.40e-08 | 5.24e-02 | -0.0481 |
79048 | SECISBP2 | A002-C-116 | Human | Colorectum | FAP | 2.34e-29 | -2.38e-01 | -0.0452 |
79048 | SECISBP2 | A014-C-008 | Human | Colorectum | FAP | 5.23e-10 | -9.63e-02 | -0.191 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
GO:0031330 | Colorectum | AD | negative regulation of cellular catabolic process | 104/3918 | 262/18723 | 2.66e-12 | 3.96e-10 | 104 |
GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
GO:1903312 | Colorectum | AD | negative regulation of mRNA metabolic process | 37/3918 | 92/18723 | 1.95e-05 | 4.01e-04 | 37 |
GO:1902369 | Colorectum | AD | negative regulation of RNA catabolic process | 30/3918 | 75/18723 | 1.30e-04 | 1.87e-03 | 30 |
GO:0000956 | Colorectum | AD | nuclear-transcribed mRNA catabolic process | 40/3918 | 112/18723 | 2.11e-04 | 2.79e-03 | 40 |
GO:1902373 | Colorectum | AD | negative regulation of mRNA catabolic process | 24/3918 | 63/18723 | 1.34e-03 | 1.17e-02 | 24 |
GO:0006414 | Colorectum | AD | translational elongation | 21/3918 | 55/18723 | 2.53e-03 | 1.93e-02 | 21 |
GO:19033112 | Colorectum | MSS | regulation of mRNA metabolic process | 115/3467 | 288/18723 | 1.23e-17 | 6.41e-15 | 115 |
GO:00064012 | Colorectum | MSS | RNA catabolic process | 102/3467 | 278/18723 | 5.07e-13 | 1.02e-10 | 102 |
GO:00064022 | Colorectum | MSS | mRNA catabolic process | 89/3467 | 232/18723 | 8.70e-13 | 1.60e-10 | 89 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SECISBP2 | SNV | Missense_Mutation | rs149816537 | c.1880N>A | p.Arg627His | p.R627H | Q96T21 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD |
SECISBP2 | SNV | Missense_Mutation | novel | c.1741N>T | p.Pro581Ser | p.P581S | Q96T21 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-HU-A4H8-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | didox | PD |
SECISBP2 | SNV | Missense_Mutation | rs777059078 | c.1879N>T | p.Arg627Cys | p.R627C | Q96T21 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
SECISBP2 | insertion | Frame_Shift_Ins | novel | c.1355_1356insG | p.Met455HisfsTer105 | p.M455Hfs*105 | Q96T21 | protein_coding | TCGA-BR-4292-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SECISBP2 | SNV | Missense_Mutation | novel | c.1267N>C | p.Glu423Gln | p.E423Q | Q96T21 | protein_coding | tolerated(0.38) | benign(0.007) | TCGA-EL-A4K9-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SECISBP2 | insertion | Frame_Shift_Ins | novel | c.695_696insAGACTATTGC | p.Asn232LysfsTer41 | p.N232Kfs*41 | Q96T21 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
SECISBP2 | insertion | Frame_Shift_Ins | novel | c.1820_1821insA | p.Asp608GlyfsTer16 | p.D608Gfs*16 | Q96T21 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
SECISBP2 | insertion | In_Frame_Ins | novel | c.1822_1823insTTT | p.Asp608delinsValTyr | p.D608delinsVY | Q96T21 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
SECISBP2 | insertion | Frame_Shift_Ins | novel | c.2259_2260insTTTATATCCAA | p.Gly754PhefsTer16 | p.G754Ffs*16 | Q96T21 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |